VT103 NEW
| Price | $120 | $297 | $471 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: VT103 | CAS No.: 2290608-13-6 |
| Purity: 99.58% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | VT103 |
| Description | VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation and is an analog of VT101. VT103 has potential antitumor activity by inhibiting YAP/TAZ-TEAD-promoted gene transcriptionment, blocking TEAD auto-palmitoylation, and blocking the interaction between YAP/TAZ and TEAD.VT103 can be used in the study of HER2-positive breast cancer, prostate cancer, and triple-negative breast cancer. |
| In vitro | VT103 (3 mmol/L; 4 or 24 h; NF2-deficient NCI-H226 cells) selectively disrupts YAP–TEAD1 interaction.[1] VT103 (3 μM; HEK293T cells) appeared to be TEAD1-selective, as it does not block palmitoylation of TEAD2, TEAD3, or TEAD4.[1] VT103 results in the disappearance of palmitoylated TEAD1 with a concomitant increase in unpalmitoylated TEAD1. VT103 shows an IC50 of 1.02 nM in the YAP reporter assay.[1] |
| In vivo | VT103 (0.3~10 mg/kg; p.o.; once daily; NCI-H226-tumor-bearing mice) inhibits tumor growth, with efficacy observed at 0.3 mg/kg[1]. Pharmacokinetics of VT103 in mice.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 7 mg/mL (17.06 mM), Solution. DMSO : 70 mg/mL (170.56 mM), Sonication is recommended. 10% DMSO+90% Saline : < 7 mg/mL (17.06 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% Corn Oil : 2.5 mg/mL (6.09 mM), Sonication is recommended. |
| Keywords | YAP–TEAD | VT103 |
| Inhibitors Related | IAG933 | AICAR | MY-1076 | Verteporfin | DC-TEADin02 | MSC-4106 | Thiostrepton | OPN-9652 | VT107 | alpha-Ionone | VT104 | MYF-01-37 |
| Related Compound Libraries | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Anti-Prostate Cancer Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Wnt/Hedgehog/Notch Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY